Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ANAPTYSBIO, INCANAB · Entity 4640 | Chief Financial Officer | February 08, 2019 | February 11, 2019 |
| Oric Pharmaceuticals, Inc.ORIC · Entity 4765 | Chief Financial Officer | September 24, 2026 | September 25, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ANAPTYSBIO, INC
Report date February 08, 2019 · Filed February 11, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $68.89 · Expires 2029-02-07 | Direct | 35,000 |
Reported balance
After 2019-02-08 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-02-08 · Grant · Acquired 35,000 · Balance 35,000 F1: The stock option vests and becomes exercisable as to 25% of the shares subject to the option on February 8, 2020, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option vests and becomes exercisable as to 25% of the shares subject to the option on February 8, 2020, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date.
Oric Pharmaceuticals, Inc.
Report date September 24, 2026 · Filed September 25, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 69,828 |
Ending reported balance
After 2026-09-24 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2026-09-24 · Exercise / conversion · Acquired 600 · Balance 70,428 Row 2 · 2026-09-24 · Sale · Disposed 100 · Balance 70,328 F1: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 26, 2026. Row 3 · 2026-09-24 · Sale · Disposed 500 · Balance 69,828 F1: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 26, 2026. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.36 · Expires 2032-07-19 | Direct | 91,900 |
Reported balance
After 2026-09-24 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-09-24 · Exercise / conversion · Disposed 600 · Balance 91,900 |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 26, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 24, 2026 Filed Sep 25, 2026 23:59 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | Exercise / conversionStock Option (right to buy) · Derivative | 600 | $0.00 Strike: $4.36 | $0.00 |
DisclosureSEC source: 0001695028-26-000008 · form4-09252026_110926.xml · derivative · entry 4 Piscitelli Dominic · CIK 0001695028 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 91,900 Underlying: Common Stock · 600 shares Expires 2032-07-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 24, 2026 Filed Sep 25, 2026 23:59 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | SaleCommon Stock | 500 | $13.51 | $6,752.50 |
DisclosureSEC source: 0001695028-26-000008 · form4-09252026_110926.xml · nonDerivative · entry 3 Piscitelli Dominic · CIK 0001695028 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 69,828 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 26, 2026. Read SEC document |
| September 24, 2026 Filed Sep 25, 2026 23:59 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | SaleCommon Stock | 100 | $13.50 | $1,350.00 |
DisclosureSEC source: 0001695028-26-000008 · form4-09252026_110926.xml · nonDerivative · entry 2 Piscitelli Dominic · CIK 0001695028 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 70,328 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 26, 2026. Read SEC document |
| September 24, 2026 Filed Sep 25, 2026 23:59 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | Exercise / conversionCommon Stock | 600 | $4.36 | $2,616.00 |
DisclosureSEC source: 0001695028-26-000008 · form4-09252026_110926.xml · nonDerivative · entry 1 Piscitelli Dominic · CIK 0001695028 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 70,428 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 26, 2026 Filed Aug 28, 2026 16:11 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | Exercise / conversionStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $6.00 | $0.00 |
DisclosureSEC source: 0001695028-26-000006 · form4-08282026_080834.xml · derivative · entry 5 Piscitelli Dominic · CIK 0001695028 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 120,000 Underlying: Common Stock · 25,000 shares Expires 2033-01-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 25% of the shares subject to the option vested on February 1, 2024, and 1/36th of the remaining shares subject to the option shall vest each month thereafter. Read SEC document |
| August 26, 2026 Filed Aug 28, 2026 16:11 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | Exercise / conversionStock Option (right to buy) · Derivative | 52,000 | $0.00 Strike: $4.36 | $0.00 |
DisclosureSEC source: 0001695028-26-000006 · form4-08282026_080834.xml · derivative · entry 4 Piscitelli Dominic · CIK 0001695028 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 92,500 Underlying: Common Stock · 52,000 shares Expires 2032-07-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 26, 2026 Filed Aug 28, 2026 16:11 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | SaleCommon Stock | 77,000 | $13.69 | $1,053,814.30 |
DisclosureSEC source: 0001695028-26-000006 · form4-08282026_080834.xml · nonDerivative · entry 3 Piscitelli Dominic · CIK 0001695028 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 69,828 F2 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 26, 2026. Read SEC document |
| August 26, 2026 Filed Aug 28, 2026 16:11 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | Exercise / conversionCommon Stock | 25,000 | $6.00 | $150,000.00 |
DisclosureSEC source: 0001695028-26-000006 · form4-08282026_080834.xml · nonDerivative · entry 2 Piscitelli Dominic · CIK 0001695028 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 146,828 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 26, 2026 Filed Aug 28, 2026 16:11 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | Exercise / conversionCommon Stock | 52,000 | $4.36 | $226,720.00 |
DisclosureSEC source: 0001695028-26-000006 · form4-08282026_080834.xml · nonDerivative · entry 1 Piscitelli Dominic · CIK 0001695028 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 121,828 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 1,680 shares of Common Stock acquired under the Issuer's 2020 Employee Stock Purchase Plan. Read SEC document |
| February 24, 2026 Filed Feb 26, 2026 21:47 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | Exercise / conversionStock Option (right to buy) · Derivative | 52,000 | $0.00 Strike: $4.36 | $0.00 |
DisclosureSEC source: 0001695028-26-000004 · form4-02262026_090218.xml · derivative · entry 3 Piscitelli Dominic · CIK 0001695028 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 144,500 Underlying: Common Stock · 52,000 shares Expires 2032-07-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 24, 2026 Filed Feb 26, 2026 21:47 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | SaleCommon Stock | 52,000 | $13.51 | $702,686.40 |
DisclosureSEC source: 0001695028-26-000004 · form4-02262026_090218.xml · nonDerivative · entry 2 Piscitelli Dominic · CIK 0001695028 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 68,148 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 24, 2025. F2 · price: Represents the weighted average share price of an aggregate total of 52,000 shares sold in the price range of $13.50 to $13.53 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 24, 2026 Filed Feb 26, 2026 21:47 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | Exercise / conversionCommon Stock | 52,000 | $4.36 | $226,720.00 |
DisclosureSEC source: 0001695028-26-000004 · form4-02262026_090218.xml · nonDerivative · entry 1 Piscitelli Dominic · CIK 0001695028 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 120,148 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 21:42 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | GrantRestricted Stock Unit · Derivative | 34,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001695028-26-000002 · form4-01062026_090131.xml · derivative · entry 2 Piscitelli Dominic · CIK 0001695028 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,500 Underlying: Common Stock · 34,500 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ORIC Pharmaceuticals, Inc. Common Stock. F3 · derivative.exercise_date: 1/3rd of the RSUs subject to the award shall vest on each of December 15, 2026, December 15, 2027 and December 15, 2028. F3 · derivative.expiration_date: 1/3rd of the RSUs subject to the award shall vest on each of December 15, 2026, December 15, 2027 and December 15, 2028. Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 21:42 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | GrantStock Option (right to buy) · Derivative | 206,500 | $0.00 Strike: $8.17 | $0.00 |
DisclosureSEC source: 0001695028-26-000002 · form4-01062026_090131.xml · derivative · entry 1 Piscitelli Dominic · CIK 0001695028 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 206,500 Underlying: Common Stock · 206,500 shares Expires 2036-01-01 F1 · derivative.exercise_date: 25% of the shares subject to the option shall vest on January 2, 2027, and 1/36th of the remaining shares subject to the option shall vest each month thereafter. Read SEC document |
| December 16, 2025 Filed Dec 18, 2025 00:19 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | SaleCommon Stock | 10,720 | $9.06 | $97,127.49 |
DisclosureSEC source: 0001695028-25-000008 · form4-12182025_121249.xml · nonDerivative · entry 2 Piscitelli Dominic · CIK 0001695028 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 68,148 F3 · kind: Represents the number of shares sold to cover the tax withholding obligations in connection with the vesting of RSUs and does not represent a discretionary sale by the Reporting Person. F4 · price: Represents the weighted average share price of an aggregate total of 10,720 shares sold in the price range of $9.0396 to $9.1953 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 15, 2025 Filed Dec 18, 2025 00:19 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | Exercise / conversionRestricted Stock Unit · Derivative | 11,333 | $0.00 | $0.00 |
DisclosureSEC source: 0001695028-25-000008 · form4-12182025_121249.xml · derivative · entry 5 Piscitelli Dominic · CIK 0001695028 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,667 Underlying: Common Stock · 11,333 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ORIC Pharmaceuticals, Inc. (the "Issuer") Common Stock. F7 · derivative.exercise_date: 1/3 of the RSUs subject to the award shall vest on each of December 15, 2025, December 15, 2026 and December 15, 2027. F7 · derivative.expiration_date: 1/3 of the RSUs subject to the award shall vest on each of December 15, 2025, December 15, 2026 and December 15, 2027. Read SEC document |
| December 15, 2025 Filed Dec 18, 2025 00:19 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | Exercise / conversionRestricted Stock Unit · Derivative | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001695028-25-000008 · form4-12182025_121249.xml · derivative · entry 4 Piscitelli Dominic · CIK 0001695028 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ORIC Pharmaceuticals, Inc. (the "Issuer") Common Stock. F6 · derivative.exercise_date: 1/3 of the RSUs subject to the award shall vest on each of December 15, 2024, December 15, 2025 and December 15, 2026. F6 · derivative.expiration_date: 1/3 of the RSUs subject to the award shall vest on each of December 15, 2024, December 15, 2025 and December 15, 2026. Read SEC document |
| December 15, 2025 Filed Dec 18, 2025 00:19 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | Exercise / conversionRestricted Stock Unit · Derivative | 8,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001695028-25-000008 · form4-12182025_121249.xml · derivative · entry 3 Piscitelli Dominic · CIK 0001695028 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ORIC Pharmaceuticals, Inc. (the "Issuer") Common Stock. F5 · derivative.exercise_date: 1/3 of the RSUs subject to the award shall vest on each of December 15, 2023, December 15, 2024 and December 15, 2025. F5 · derivative.expiration_date: 1/3 of the RSUs subject to the award shall vest on each of December 15, 2023, December 15, 2024 and December 15, 2025. Read SEC document |
| December 15, 2025 Filed Dec 18, 2025 00:19 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | Exercise / conversionCommon Stock | 29,333 | $0.00 | $0.00 |
DisclosureSEC source: 0001695028-25-000008 · form4-12182025_121249.xml · nonDerivative · entry 1 Piscitelli Dominic · CIK 0001695028 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 78,868 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ORIC Pharmaceuticals, Inc. (the "Issuer") Common Stock. F2 · balance_after: Includes 1,218 shares of Common Stock acquired under the Issuer's 2020 Employee Stock Purchase Plan. Read SEC document |
| October 06, 2025 Filed Oct 8, 2025 21:37 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | Exercise / conversionStock Option (right to buy) · Derivative | 11,000 | $0.00 Strike: $4.36 | $0.00 |
DisclosureSEC source: 0001695028-25-000004 · form4-10082025_091013.xml · derivative · entry 3 Piscitelli Dominic · CIK 0001695028 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 196,500 Underlying: Common Stock · 11,000 shares Expires 2032-07-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 06, 2025 Filed Oct 8, 2025 21:37 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | SaleCommon Stock | 11,000 | $14.52 | $159,718.90 |
DisclosureSEC source: 0001695028-25-000004 · form4-10082025_091013.xml · nonDerivative · entry 2 Piscitelli Dominic · CIK 0001695028 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 48,317 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 24, 2025. F2 · price: Represents the weighted average share price of an aggregate total of 11,000 shares sold in the price range of $14.50 to $14.53 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| October 06, 2025 Filed Oct 8, 2025 21:37 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | Exercise / conversionCommon Stock | 11,000 | $4.36 | $47,960.00 |
DisclosureSEC source: 0001695028-25-000004 · form4-10082025_091013.xml · nonDerivative · entry 1 Piscitelli Dominic · CIK 0001695028 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 59,317 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 01, 2025 Filed Jul 2, 2025 20:07 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | SaleCommon Stock | 20,000 | $10.05 | $200,972.00 |
DisclosureSEC source: 0001415889-25-019000 · form4-07022025_080708.xml · nonDerivative · entry 1 Piscitelli Dominic · CIK 0001695028 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 48,317 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 30, 2024. F2 · price: Represents the weighted average share price of an aggregate total of 20,000 shares sold in the price range of $10.00 to $10.135 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| June 24, 2025 Filed Jun 24, 2025 22:33 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | SaleCommon Stock | 32,466 | $10.50 | $341,039.10 |
DisclosureSEC source: 0001415889-25-018128 · form4-06242025_100608.xml · nonDerivative · entry 3 Piscitelli Dominic · CIK 0001695028 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 68,317 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 30, 2024. F2 · price: Represents the weighted average share price of an aggregate total of 32,466 shares sold in the price range of $10.34 to $10.80 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| June 23, 2025 Filed Jun 24, 2025 22:33 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | SaleCommon Stock | 450 | $10.01 | $4,504.50 |
DisclosureSEC source: 0001415889-25-018128 · form4-06242025_100608.xml · nonDerivative · entry 2 Piscitelli Dominic · CIK 0001695028 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 100,783 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 30, 2024. Read SEC document |
| June 23, 2025 Filed Jun 24, 2025 22:33 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | SaleCommon Stock | 584 | $10.00 | $5,840.00 |
DisclosureSEC source: 0001415889-25-018128 · form4-06242025_100608.xml · nonDerivative · entry 1 Piscitelli Dominic · CIK 0001695028 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 101,233 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 30, 2024. Read SEC document |
| June 12, 2025 Filed Jun 13, 2025 23:38 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | SaleCommon Stock | 300 | $10.00 | $3,000.00 |
DisclosureSEC source: 0001415889-25-017325 · form4-06132025_110620.xml · nonDerivative · entry 1 Piscitelli Dominic · CIK 0001695028 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 101,817 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 30, 2024. Read SEC document |
| June 11, 2025 Filed Jun 11, 2025 22:37 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | SaleCommon Stock | 1,700 | $10.01 | $17,017.00 |
DisclosureSEC source: 0001415889-25-016739 · form4-06112025_100647.xml · nonDerivative · entry 3 Piscitelli Dominic · CIK 0001695028 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 102,117 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 30, 2024. Read SEC document |
| June 11, 2025 Filed Jun 11, 2025 22:37 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | SaleCommon Stock | 1,276 | $10.00 | $12,760.00 |
DisclosureSEC source: 0001415889-25-016739 · form4-06112025_100647.xml · nonDerivative · entry 2 Piscitelli Dominic · CIK 0001695028 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 103,817 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 30, 2024. Read SEC document |
| June 10, 2025 Filed Jun 11, 2025 22:37 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | SaleCommon Stock | 324 | $10.00 | $3,240.00 |
DisclosureSEC source: 0001415889-25-016739 · form4-06112025_100647.xml · nonDerivative · entry 1 Piscitelli Dominic · CIK 0001695028 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 105,093 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 30, 2024. F2 · balance_after: Includes an aggregate of 1,553 shares of Common Stock acquired under the Issuer's 2020 Employee Stock Purchase Plan. Read SEC document |
| June 09, 2025 Filed Jun 10, 2025 00:18 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | SaleCommon Stock | 300 | $10.00 | $3,000.00 |
DisclosureSEC source: 0001415889-25-016386 · form4-06102025_120617.xml · nonDerivative · entry 2 Piscitelli Dominic · CIK 0001695028 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 103,864 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 30, 2024. Read SEC document |
| June 06, 2025 Filed Jun 10, 2025 00:18 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | SaleCommon Stock | 2,600 | $10.01 | $26,021.32 |
DisclosureSEC source: 0001415889-25-016386 · form4-06102025_120617.xml · nonDerivative · entry 1 Piscitelli Dominic · CIK 0001695028 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 104,164 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 30, 2024. F2 · price: Represents the weighted average share price of an aggregate total of 2,600 shares sold in the price range of $10.00 to $10.04 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| January 02, 2025 Filed Jan 3, 2025 22:41 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | GrantRestricted Stock Unit · Derivative | 34,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-000601 · form4-01032025_100150.xml · derivative · entry 2 Piscitelli Dominic · CIK 0001695028 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,000 Underlying: Common Stock · 34,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ORIC Pharmaceuticals, Inc. Common Stock. F3 · derivative.exercise_date: 1/3rd of the RSUs subject to the award shall vest on each of December 15, 2025, December 15, 2026 and December 15, 2027. F3 · derivative.expiration_date: 1/3rd of the RSUs subject to the award shall vest on each of December 15, 2025, December 15, 2026 and December 15, 2027. Read SEC document |
| January 02, 2025 Filed Jan 3, 2025 22:41 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | GrantStock Option (right to buy) · Derivative | 202,500 | $0.00 Strike: $8.26 | $0.00 |
DisclosureSEC source: 0001415889-25-000601 · form4-01032025_100150.xml · derivative · entry 1 Piscitelli Dominic · CIK 0001695028 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 202,500 Underlying: Common Stock · 202,500 shares Expires 2035-01-01 F1 · derivative.exercise_date: 25% of the shares subject to the option shall vest on January 2, 2026, and 1/36th of the remaining shares subject to the option shall vest each month thereafter. Read SEC document |
| December 16, 2024 Filed Dec 17, 2024 22:23 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | SaleCommon Stock | 8,851 | $8.28 | $73,297.79 |
DisclosureSEC source: 0001415889-24-029634 · form4-12172024_101232.xml · nonDerivative · entry 2 Piscitelli Dominic · CIK 0001695028 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 106,764 F3 · kind: Represents the number of shares sold to cover the tax withholding obligations in connection with the vesting of RSUs and does not represent a discretionary sale by the Reporting Person. F4 · price: Represents the weighted average share price of an aggregate total of 8,851 shares sold in the price range of $8.28 to $8.41 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 15, 2024 Filed Dec 17, 2024 22:23 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | Exercise / conversionRestricted Stock Unit · Derivative | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-029634 · form4-12172024_101232.xml · derivative · entry 5 Piscitelli Dominic · CIK 0001695028 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 10,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ORIC Pharmaceuticals, Inc. (the "Issuer") Common Stock. F7 · derivative.exercise_date: 1/3 of the RSUs subject to the award shall vest on each of December 15, 2024, December 15, 2025 and December 15, 2026. F7 · derivative.expiration_date: 1/3 of the RSUs subject to the award shall vest on each of December 15, 2024, December 15, 2025 and December 15, 2026. Read SEC document |
| December 15, 2024 Filed Dec 17, 2024 22:23 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | Exercise / conversionRestricted Stock Unit · Derivative | 8,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-029634 · form4-12172024_101232.xml · derivative · entry 4 Piscitelli Dominic · CIK 0001695028 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,000 Underlying: Common Stock · 8,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ORIC Pharmaceuticals, Inc. (the "Issuer") Common Stock. F6 · derivative.exercise_date: 1/3 of the RSUs subject to the award shall vest on each of December 15, 2023, December 15, 2024 and December 15, 2025. F6 · derivative.expiration_date: 1/3 of the RSUs subject to the award shall vest on each of December 15, 2023, December 15, 2024 and December 15, 2025. Read SEC document |
| December 15, 2024 Filed Dec 17, 2024 22:23 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | Exercise / conversionRestricted Stock Unit · Derivative | 6,042 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-029634 · form4-12172024_101232.xml · derivative · entry 3 Piscitelli Dominic · CIK 0001695028 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,042 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ORIC Pharmaceuticals, Inc. (the "Issuer") Common Stock. F5 · derivative.exercise_date: 1/3 of the RSUs subject to the award shall vest on each of December 15, 2022, December 15, 2023 and December 15, 2024. F5 · derivative.expiration_date: 1/3 of the RSUs subject to the award shall vest on each of December 15, 2022, December 15, 2023 and December 15, 2024. Read SEC document |
| December 15, 2024 Filed Dec 17, 2024 22:23 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | Exercise / conversionCommon Stock | 24,042 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-029634 · form4-12172024_101232.xml · nonDerivative · entry 1 Piscitelli Dominic · CIK 0001695028 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 115,615 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ORIC Pharmaceuticals, Inc. (the "Issuer") Common Stock. F2 · balance_after: Includes an aggregate of 7,764 shares of Common Stock acquired under the Issuer's 2020 Employee Stock Purchase Plan. Read SEC document |
| January 02, 2024 Filed Jan 3, 2024 21:18 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | GrantRestricted Stock Unit · Derivative | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-24-000364 · doc4.xml · derivative · entry 2 Piscitelli Dominic · CIK 0001695028 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ORIC Pharmaceuticals, Inc. Common Stock. F3 · derivative.exercise_date: 1/3 of the RSUs subject to the award shall vest on each of December 15, 2024, December 15, 2025 and December 15, 2026. F3 · derivative.expiration_date: 1/3 of the RSUs subject to the award shall vest on each of December 15, 2024, December 15, 2025 and December 15, 2026. Read SEC document |
| January 02, 2024 Filed Jan 3, 2024 21:18 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | GrantStock Option (right to buy) · Derivative | 180,000 | $0.00 Strike: $9.14 | $0.00 |
DisclosureSEC source: 0001209191-24-000364 · doc4.xml · derivative · entry 1 Piscitelli Dominic · CIK 0001695028 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 180,000 Underlying: Common Stock · 180,000 shares Expires 2034-01-01 F1 · derivative.exercise_date: 25% of the shares subject to the option shall vest on January 2, 2025, and 1/36th of the remaining shares subject to the option shall vest each month thereafter. Read SEC document |
| December 15, 2023 Filed Dec 20, 2023 00:40 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | Exercise / conversionRestricted Stock Unit · Derivative | 8,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-059264 · doc4.xml · derivative · entry 4 Piscitelli Dominic · CIK 0001695028 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,000 Underlying: Common Stock · 8,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ORIC Pharmaceuticals, Inc. (the "Issuer") Common Stock. F6 · derivative.exercise_date: 1/3 of the RSUs subject to the award shall vest on each of December 15, 2023, December 15, 2024 and December 15, 2025. F6 · derivative.expiration_date: 1/3 of the RSUs subject to the award shall vest on each of December 15, 2023, December 15, 2024 and December 15, 2025. Read SEC document |
| December 15, 2023 Filed Dec 20, 2023 00:40 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | Exercise / conversionRestricted Stock Unit · Derivative | 6,042 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-059264 · doc4.xml · derivative · entry 3 Piscitelli Dominic · CIK 0001695028 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,042 Underlying: Common Stock · 6,042 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ORIC Pharmaceuticals, Inc. (the "Issuer") Common Stock. F5 · derivative.exercise_date: 1/3 of the RSUs subject to the award shall vest on each of December 15, 2022, December 15, 2023 and December 15, 2024. F5 · derivative.expiration_date: 1/3 of the RSUs subject to the award shall vest on each of December 15, 2022, December 15, 2023 and December 15, 2024. Read SEC document |
| December 15, 2023 Filed Dec 20, 2023 00:40 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | SaleCommon Stock | 5,282 | $8.58 | $45,338.05 |
DisclosureSEC source: 0001209191-23-059264 · doc4.xml · nonDerivative · entry 2 Piscitelli Dominic · CIK 0001695028 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 83,809 F3 · kind: Represents the number of shares sold to cover the tax withholding obligations in connection with the vesting of RSUs and does not represent a discretionary sale by the Reporting Person. F4 · price: Represents the weighted average share price of an aggregate total of 5,282 shares sold in the price range of $8.57 to $8.756 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 15, 2023 Filed Dec 20, 2023 00:40 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | Exercise / conversionCommon Stock | 14,042 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-059264 · doc4.xml · nonDerivative · entry 1 Piscitelli Dominic · CIK 0001695028 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 89,091 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ORIC Pharmaceuticals, Inc. (the "Issuer") Common Stock. F2 · balance_after: Includes an aggregate of 7,764 shares of Common Stock acquired under the Issuer's 2020 Employee Stock Purchase Plan. Read SEC document |
| February 01, 2023 Filed Feb 2, 2023 21:11 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | GrantRestricted Stock Unit · Derivative | 24,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-006195 · doc4.xml · derivative · entry 2 Piscitelli Dominic · CIK 0001695028 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,000 Underlying: Common Stock · 24,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ORIC Pharmaceuticals, Inc. Common Stock. F3 · derivative.exercise_date: 1/3 of the RSUs subject to the award shall vest on each of December 15, 2023, December 15, 2024 and December 15, 2025. F3 · derivative.expiration_date: 1/3 of the RSUs subject to the award shall vest on each of December 15, 2023, December 15, 2024 and December 15, 2025. Read SEC document |
| February 01, 2023 Filed Feb 2, 2023 21:11 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | GrantStock Option (right to buy) · Derivative | 145,000 | $0.00 Strike: $6.00 | $0.00 |
DisclosureSEC source: 0001209191-23-006195 · doc4.xml · derivative · entry 1 Piscitelli Dominic · CIK 0001695028 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,000 Underlying: Common Stock · 145,000 shares Expires 2033-01-31 F1 · derivative.exercise_date: 25% of the shares subject to the option shall vest on February 1, 2024, and 1/36th of the remaining shares subject to the option shall vest each month thereafter. Read SEC document |
| December 15, 2022 Filed Dec 17, 2022 01:49 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | Exercise / conversionRestricted Stock Unit · Derivative | 6,041 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-061755 · doc4.xml · derivative · entry 3 Piscitelli Dominic · CIK 0001695028 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,084 Underlying: Common Stock · 6,041 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ORIC Pharmaceuticals, Inc. (the "Issuer") Common Stock. F4 · derivative.exercise_date: 1/3 of the RSUs subject to the award shall vest on each of December 15, 2022, December 15, 2023 and December 15, 2024. F4 · derivative.expiration_date: 1/3 of the RSUs subject to the award shall vest on each of December 15, 2022, December 15, 2023 and December 15, 2024. Read SEC document |
| December 15, 2022 Filed Dec 17, 2022 01:49 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | SaleCommon Stock | 2,089 | $3.25 | $6,789.25 |
DisclosureSEC source: 0001209191-22-061755 · doc4.xml · nonDerivative · entry 2 Piscitelli Dominic · CIK 0001695028 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,423 F3 · kind: Represents the number of shares sold to cover the tax withholding obligations in connection with the vesting of RSUs and does not represent a discretionary sale by the Reporting Person. Read SEC document |
| December 15, 2022 Filed Dec 17, 2022 01:49 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | Exercise / conversionCommon Stock | 6,041 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-061755 · doc4.xml · nonDerivative · entry 1 Piscitelli Dominic · CIK 0001695028 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,512 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ORIC Pharmaceuticals, Inc. (the "Issuer") Common Stock. F2 · balance_after: Includes an aggregate of 3,471 shares of Common Stock acquired under the Issuer's 2020 Employee Stock Purchase Plan.. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.